Biotechnology company focused on cellular rejuvenation and partial epigenetic reprogramming to restore cellular health and reverse disease/injury. Launched in 2022 with an estimated ~$3.000M in funding backed by investors such as Jeff Bezos; operates in the Bay Area (Redwood City), San Diego, and Cambridge (UK). Led by Hal Barron, MD (CEO and co-founder) alongside founders such as Rick Klausner, H...